Ionis Pharmaceuticals received FDA Priority Review for olezarsen, a treatment for severe hypertriglyceridemia, with a PDUFA date set for June 30. The company also announced it will present new Phase 3 data for its hereditary angioedema therapy, DAWNZERA, at a major medical conference. Financially, the company provided strong revenue guidance for 2026 and reported significant revenue growth for 2025, while highlighting commercial traction for its key products.